$RZLT

4 stories mentioning RZLTUpdated just now

Every FINWIRES story that references RZLT, newest first.

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks were lower late Wednesday afternoon with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding 0.2%.The iShares Biotechnology ETF (IBB) declined 0.8%.In corporate news, UnitedHealth (UNH) sold an interest in some of its Optum Health operations in Florida to TPG (TPG), Bloomberg reported. UnitedHealth shares were down 2.2%.Agilent Technologies (A) shares fell 1.2% after UBS downgraded the stock to neutral from buy.Rezolute (RZLT) said Wednesday that the US Food and Drug Administration is still reviewing data from a phase 3 study of ersodetug for the potential treatment of hypoglycemia due to congenital hyperinsulinism. The company said it does not have a specific timeline on when it will receive feedback or guidance from the FDA on potential next steps. Rezolute shares were down past 7%.Opus Genetics (IRD) shares jumped 35% after it said that patients with Bestrophin-1-related retinal diseases showed clinically meaningful improvement in visual function in the low-dose cohort 1 of its BIRD-1 phase 1/2 trial evaluating OPGx-BEST1.

$A$IRD$RZLT$UNH

Sectors5h ago

Sector Update: Healthcare Stocks Decline in Afternoon Trading

Healthcare stocks were lower Wednesday afternoon, with the NYSE Healthcare Index down 0.3% and the State Street Health Care Select Sector SPDR ETF (XLV) easing 0.2%.The iShares Biotechnology ETF (IBB) decreased 0.6%.In corporate news, UnitedHealth (UNH) sold an interest in some of its Optum Health operations in Florida to TPG (TPG), Bloomberg reported. UnitedHealth shares were down 1.8%.Evommune's (EVMN) phase 2b trial of EVO756 to treat adults with moderate-to-severe atopic dermatitis didn't meet its primary and secondary endpoints in any of the doses studied, the company said. Its shares fell past 16%.Rezolute (RZLT) said Wednesday that the US Food and Drug Administration is still reviewing data from a phase 3 study of ersodetug for the potential treatment of hypoglycemia due to congenital hyperinsulinism. The company said it does not have a specific timeline on when it will receive feedback or guidance from the FDA on potential next steps. Rezolute shares were down past 7%.

$EVMN$RZLT$UNH

Wire15d ago

Rezolute Shares to Show Strength Towards Upcoming Ersodetug Catalysts, Wedbush Says

Rezolute (RZLT) shares are poised to show strength towards upcoming ersodetug catalysts, with Sunrize phase 3 trial in congenital hyperinsulinism program update slated for mid-September and topline data from the Uplift phase 3 study in tumor HI expected in H2, Wedbush said in a Tuesday note.Wedbush said it continues to believe that the requirement for a small supplemental study, to be actively ongoing at the time of biologics license application with currently available data, could be the most likely path forward for ersodetug in congenital HI.Additionally, the US Food and Drug Administration's recognition of the increasing use of continuous glucose monitor in clinical practice could bode well for the agency's feedback on ersodetug's pathway forward in congenital HI, according to the note.Wedbush maintained its outperform rating with a $6 price target.Price: $5.08, Change: $+0.07, Percent Change: +1.40%

$RZLT

Wire99d ago

Update: Rezolute Shares Rise After Participants Meet Responder Criterion in Phase 3 Tumor Hyperinsulinism Trial

(Updates with the latest stock move in the headline and in the first paragraph.)Rezolute (RZLT) shares rose about 16% in Tuesday afternoon trading after the company said that six of eight participants enrolled in a phase 3 trial of ersodetug in uncontrolled hypoglycemia caused by tumor hyperinsulinism have already met the responder criterion for the study's primary endpoint.The primary endpoint of the study, which aims to enroll 16 patients with insulinoma or non-islet cell tumors, is the number of participants achieving at least a 50% reduction from baseline in intravenous glucose requirements within the 8-week pivotal treatment phase, the company said.Rezolute said ersodetug has been well-tolerated in the pivotal and extension phases of the study, with no drug-related adverse events or other safety findings reported to date.Topline results for the fully enrolled open-label phase 3 study are expected in H2, Rezolute said.Price: $4.18, Change: $+0.57, Percent Change: +15.65%

$RZLT

Track with the FINWIRES app suite

FolioX

Track RZLT in your portfolio

WheelAI

Analyze RZLT options with the wheel strategy

StockInsider

See market sentiment on RZLT